By Suvarna Bhatt
San Francisco, April 13 (BioSpace) – Auckland, New Zealand based Neuren Pharmaceuticals Ltd. has successfully completed its phase 2 trial of Glypromate(R).
An independent Data Safety Monitoring Committee has confirmed the drug’s clean safety profile. An Investigational New Drug application to the US Food and Drug Administration is planned to begin a Phase 3 trial later this year.
Contact Suvarna Bhatt at sbhatt@biospace.com.
